Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) to Ring The Nasdaq Stock Market Opening Bell
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
- Qualcomm shares fall on Intel warning and legal concerns
- Marvell Technology shares drop on Lumentum deal concerns
- Oracle shares drop on AI spending concerns and Microsoft criticism
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- SpaceX stock drops on launch setback and sector selloff
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Baird Reiterates Outperform on Regeneron (REGN) Following Positive Phase III Data
April 1, 2016 11:52 AM EDTBaird reiterated an Outperform rating and $526.00 price target on Regeneron Pharma (NASDAQ: REGN) following the company's release of Dupilumab's phase III atopic dermatitis phase III data. The two Phase III studies, SOLO 1 and SOLO 2, enrolled 1,379 adult patients with moderate-to-severe AD. The FDA's... More



